On June 17, 2025, analyst Arthur He from HC Wainwright & Co. reaffirmed a "Buy" rating for Solid Biosciences (SLDB, Financial). The decision follows the analyst's assessment of the company's current position and future prospects, maintaining confidence in its performance.
The price target for Solid Biosciences (SLDB, Financial) remains steady at $20.00, unchanged from the previous target. This consistent price target indicates continued optimism about the stock's potential value in the market.
Solid Biosciences (SLDB, Financial), which trades on the NASDAQ, continues to capture the interest of investors based on its strategic initiatives and ongoing developments. The company's stock remains a topic of focus for market watchers given the reiterated endorsement from HC Wainwright & Co.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Solid Biosciences Inc (SLDB, Financial) is $16.11 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 220.94% from the current price of $5.02. More detailed estimate data can be found on the Solid Biosciences Inc (SLDB) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Solid Biosciences Inc's (SLDB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
